Authors:
VAHDAT LT
PAPADOPOULOS K
BALMACEDA C
MCGOVERN T
DUNLEAVY J
KAUFMAN E
FUNG B
GARRETT T
SAVAGE D
TIERSTEN A
AYELLO J
BAGIELLA E
HEITJAN D
ANTMAN K
HESDORFFER C
Citation: Lt. Vahdat et al., PHASE-I TRIAL OF SEQUENTIAL HIGH-DOSE CHEMOTHERAPY WITH ESCALATING DOSE PACLITAXEL, MELPHALAN, AND CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN WITH PERIPHERAL-BLOOD PROGENITOR SUPPORT IN WOMEN WITH RESPONDING METASTATIC BREAST-CANCER, Clinical cancer research, 4(7), 1998, pp. 1689-1695
Authors:
HOGARTH PM
POWELL M
BARNES N
WINES B
GAVIN A
MAXWELL K
GARRETT T
COLMAN P
MCKENZIE IFC
Citation: Pm. Hogarth et al., THE 3-D STRUCTURE OF FCGAMMARII AND IDENTIFICATION OF THE BINDING-SITES OF RELATED RECEPTORS COMBINED WITH GENE INACTIVATION STUDIES IDENTIFY NEW PERSPECTIVES ON THE ROLE OF FC-RECEPTORS IN IMMUNITY, The FASEB journal, 12(5), 1998, pp. 5282-5282
Authors:
HESDORFFER C
AYELLO J
WARD M
KAUBISCH A
VAHDAT L
BALMACEDA C
GARRETT T
FETELL M
REISS R
BANK A
ANTMAN K
Citation: C. Hesdorffer et al., PHASE-I TRIAL OF RETROVIRAL-MEDIATED TRANSFER OF THE HUMAN MDR1 GENE AS MARROW CHEMOPROTECTION IN PATIENTS UNDERGOING HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION, Journal of clinical oncology, 16(1), 1998, pp. 165-172
Citation: We. Souder et al., SUCCESS THROUGH CUSTOMER-DRIVEN NEW PRODUCT DEVELOPMENT - A COMPARISON OF US AND NEW-ZEALAND SMALL ENTREPRENEURIAL HIGH-TECHNOLOGY FIRMS, The Journal of product innovation management, 14(6), 1997, pp. 459-472